ERBB2 and breast cancer: The median overall survival today for stage IV HR-positive or ERBB2-positive BC is over 5 years.40 Previous costing analyses looked only at BC treatment costs over a defined time frame, often 2 years, while activity-based costing captures the entire cost for the treatment for each case of BC, independent of duration.41